磷酸二酯酶-4抑制剂治疗掌跖脓疱病的研究进展
Research progress on phosphodiesterase 4 inhibitors in the treatment of palmoplantar pustulosis
姚心怡 1高文丽 1李娟 1张峻岭2
作者信息
- 1. 天津中医药大学研究生院,天津 301617
- 2. 天津市中医药研究院附属医院,天津 300120
- 折叠
摘要
掌跖脓疱病(PPP)是一种慢性复发性炎症性皮肤疾病,现有治疗手段不能满足患者需求.磷酸二酯酶-4(PDE-4)是参与免疫细胞体内平衡的关键酶,在PPP相关的多种炎症信号传导途径中充当下游介质,广泛调节免疫反应.口服PDE-4抑制剂阿普米司特(Apremilast)在PPP的临床实验中表现优越,克立硼罗软膏(Crisaborole)也有报道可使皮损持续改善.本文就PDE-4抑制剂治疗PPP的研究进展作一概述.
Abstract
Palmoplantar pustulosis(PPP)is a chronic recurrent inflammatory skin disease.Existing therapeutic methods cannot meet the demand by patients.Phosphodiesterase-4(PDE-4)is a key enzyme involved in the balance of immunocytes.It acts as a downstream mediator in the signaling pathways of a variety of cytokines which are associated with palmoplantar pustulosis and extensively regulate immune responses.Apremilast,as representative of the oral PDE-4 inhibitors,displays superior efficacy in clinical trials against palmoplantar pustulosis.Crisaborole has also been regulate to induce sustained improvement in skin lesions.This article reviews the research progress on PDE-4 inhibitors in treatment of palmoplantar pustulosis.
关键词
掌跖脓疱病/磷酸二酯酶-4抑制剂/阿普米司特/克立硼罗Key words
palmoplantar pustulosis/PDE-4 inhibitor/Apremilast/Crisaborole引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据